Hormone-replacement therapy is a critical component of many transgender individual’s gender affirmation process. Lack of access to these vital medications may potentially pose a serious health threat to them.
HRC Reports that the shortage began 18 months ago when the 40 mg dosage of injectable estrogen went on the drug shortage list and has not since returned to the marketplace.
This is the highest dosage available and the one most frequently prescribed to transgender women. Doctors then began doubling up on dosages of the 20 mg injectables, which have become scarce this summer.
While estrogen in pill or patch form continue to remain available, the injectable form is preferred by many trans women and health professionals are concerned that these women may turn to unregulated sources such as the street or black market online pharmacies that ship drugs from other countries.
HRC reached out to the U.S. Food and Drug Administration (FDA) officials to express concern about the shortage and to learn what the agency is currently doing to address the ongoing problem. In addition, HRC partnered with the National Center for Transgender Equality on a letter to FDA Commissioner Dr. Robert Califf urging that the agency expedite review of information necessary to approve the drug and bring the shortage to an end. They announced.